Key references: Drug-induced liver injury
- Bjornsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci 2016;17(2):224. https://www.ncbi.nlm.nih.gov/pubmed/26861310
- De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68(6):1181–90. https://www.ncbi.nlm.nih.gov/pubmed/29427729
- European Association for the Study of the Liver. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol 2019;70(6):1222–61. https://www.ncbi.nlm.nih.gov/pubmed/30926241
- Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry 2015;3(1):4. https://www.ncbi.nlm.nih.gov/pubmed/25932327
- Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med 2019;381(3):264–73. https://www.ncbi.nlm.nih.gov/pubmed/31314970
- LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. https://www.ncbi.nlm.nih.gov/books/NBK547852/
- Therapeutic Goods Administration (TGA). Database of adverse event notifications - medicines: List of reports - Agomelatine/Valdoxan. Canberra: TGA. https://apps.tga.gov.au/PROD/DAEN/daen-entry.aspx